Regeneron’s Casirivimab and Imdevimab Antibody Cocktail for COVID-19 is First Combination Therapy to Receive FDA Emergency Use Authorization

TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered…

FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis

NEW YORK–(BUSINESS WIRE) October 27, 2020 — Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration…